Marcus Taylor

Dr. Marcus Taylor

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2019 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
VMVipin Mehta
Vipin Mehta
MTMarcus Taylor
Marcus Taylor
JHJoanne Hasan
Joanne Hasan
IDIoannis Dimarakis
Ioannis Dimarakis
JBJim Barnard
Jim Barnard
RVRajamiyer V Venkateswaran
Rajamiyer V Venkateswaran
Demand for heart transplant donors worldwide continues to outstrip supply. Transplanting hearts following donation after circulatory-determined death (DCD) is increasingly recognized as a safe and effective alternative. As the fourth centre worldwide to have established such a programme, our goal was to present our initial experience. This was a single-centre retrospective observational study. All DCD hearts were retrieved using direct procurement and perfusion. Continuous normothermic perfusion of the procured heart was then established on the TransMedics® Organ Care System. The primary outcome of this study was the 30-day survival rate. Between May 2017 and December 2018, 8 DCD hearts were procured and 7 were subsequently implanted, including in 2 patients who had left ventricular assist devices explanted. During the same time period, 30 patients received donation after brainstem death heart transplants. Therefore, the DCD heart transplant programme led to a 23% increase in transplant activity. The median donation warm ischaemic time was 34 min [interquartile range (IQR) 31–39 min]. The median functional warm ischaemic time was 28 min (IQR 25–30 min). The median time spent by the organ on the Organ Care System was 263 min (IQR 242–296 min). The overall 30-day survival rate was 100% and the 90-day survival rate was 86%. Postoperative extracorporeal membrane oxygenation was required in 3/7 (43%). DCD heart transplants can lead to a 23% increase in heart transplant activity and should be adopted by more institutions across the world. Already established transplant programmes with good early outcomes can start such a programme safely.

25 May 2024 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MTMarcus Taylor
Marcus Taylor
MEMatt Evison
Matt Evison
SMSarah Michael
Sarah Michael
EOEmmanuel Obale
Emmanuel Obale
NFNils C. Fritsch
Nils C. Fritsch
SGStuart W. Grant
Stuart W. Grant

12 July 2022 in British Journal of Anaesthesia
Verified
Journal Article
Open access
PBPatrick Bradley
Patrick Bradley
ZMZoe Merchant
Zoe Merchant
KRKirsty Rowlinson-Groves
Kirsty Rowlinson-Groves
MTMarcus Taylor
Marcus Taylor
JMJohn Moore
John Moore
MEMatthew Evison
Matthew Evison
Prehabilitation, or multimodality patient optimisation before major treatment, has demonstrated meaningful improvements in patients' outcomes. In the setting of lung cancer surgery, postoperative complications and length of hospital stay are reduced, but there is currently limited access to prehabilitation. Prehab4Cancer (P4C) is an innovative regional programme serving all areas of Greater Manchester (GM). The lung cancer P4C service commenced in 2019 as a collaboration between the GM Cancer alliance and 12 leisure and community organisations. Patients planning surgical resection could be referred to receive exercise, nutrition, and well-being assessment and interventions before surgery. We evaluated the programme's feasibility, uptake, and outcomes during the 11 months before COVID-19 restrictions. In total, 377 patients were referred to the lung cancer P4C service from all 11 hospitals in GM. Of the patients reached by telephone, 80.0% (n=280/348) attended initial P4C assessment, which occurred a median of 8 days (inter-quartile range [IQR]: 4–14) after referral. In addition, 74.3% (n=280/377) attended for baseline assessment and 47.7% (n=180/377) completed prehabilitation, attending a median of six sessions (IQR: 4–9). Statistically significant improvements in all objective physiological and subjective functional assessments were observed preoperatively, including a mean increase in the incremental shuttle walk test of 50 m (95% confidence interval: 25–74; P<0.001). The P4C programme demonstrated feasibility at scale, high uptake, and promising impact on the status of patients with lung cancer before surgery. P4C is the first regional prehabilitation service internationally, and this evaluation provides a framework for implementing similar services in other regions.

24 November 2020 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
MTMarcus Taylor
Marcus Taylor
BSBartłomiej Szafron
Bartłomiej Szafron
GMGlen P Martin
Glen P Martin
UAUdo Abah
Udo Abah
MSMatthew Smith
Matthew Smith
SGStuart W Grant
Stuart W Grant
: OBJECTIVES: National guidelines advocate the use of clinical prediction models to estimate perioperative mortality for patients undergoing lung resection. Several models have been developed that may potentially be useful but contemporary external validation studies are lacking. The aim of this study was to validate existing models in a multicentre patient cohort. METHODS: The Thoracoscore, Modified Thoracoscore, Eurolung, Modified Eurolung, European Society Objective Score and Brunelli models were validated using a database of 6600 patients who underwent lung resection between 2012 and 2018. Models were validated for in-hospital or 30-day mortality (depending on intended outcome of each model) and also for 90-day mortality. Model calibration (calibration intercept, calibration slope, observed to expected ratio and calibration plots) and discrimination (area under receiver operating characteristic curve) were assessed as measures of model performance. RESULTS: Mean age was 66.8 years (±10.9 years) and 49.7% (n = 3281) of patients were male. In-hospital, 30-day, perioperative (in-hospital or 30-day) and 90-day mortality were 1.5% (n = 99), 1.4% (n = 93), 1.8% (n = 121) and 3.1% (n = 204), respectively. Model area under the receiver operating characteristic curves ranged from 0.67 to 0.73. Calibration was inadequate in five models and mortality was significantly overestimated in five models. No model was able to adequately predict 90-day mortality. CONCLUSIONS: Five of the validated models were poorly calibrated and had inadequate discriminatory ability. The modified Eurolung model demonstrated adequate statistical performance but lacked clinical validity. Development of accurate models that can be used to estimate the contemporary risk of lung resection is required.

6 December 2021 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
ABAnnemarie Brunswicker
Annemarie Brunswicker
MTMarcus Taylor
Marcus Taylor
SGStuart W Grant
Stuart W Grant
UAUdo Abah
Udo Abah
MSMatthew Smith
Matthew Smith
NFNilsCristopher Fritsch
NilsCristopher Fritsch
Despite the increased rate of adverse outcomes compared to lobectomy, for selected patients with lung cancer, pneumonectomy is considered the optimal treatment option. The objective of this study was to identify risk factors for mortality in patients undergoing pneumonectomy for primary lung cancer. Data from all patients undergoing pneumonectomy for primary lung cancer at 2 large thoracic surgical centres between 2012 and 2018 were analysed. Multivariable logistic and Cox regression analyses were used to identify risk factors associated with 90-day and 1-year mortality and reduced long-term survival, respectively. The study included 256 patients. The mean age was 65.2 (standard deviation 9.4) years. In-hospital, 90-day and 1-year mortality were 6.3% (n = 16), 9.8% (n = 25) and 28.1% (n = 72), respectively. The median follow-up time was 31.5 months (interquartile range 9–58 months). Patients who underwent neoadjuvant therapy had a significantly increased risk of 90-day [odds ratio 6.451, 95% confidence interval (CI) 1.867–22.291, P = 0.003] and 1-year mortality (odds ratio 2.454, 95% CI 1.079–7.185, P = 0.044). Higher Performance Status score was associated with higher 1-year mortality (odds ratio 2.055, 95% CI 1.248–3.386, P = 0.005) and reduced overall survival (hazard ratio 1.449, 95% CI 1.086–1.934, P = 0.012). Advanced (stage III/IV) disease was associated with reduced overall survival (hazard ratio 1.433, 95% CI 1.019–2.016, P = 0.039). Validation of a pneumonectomy-specific risk model demonstrated inadequate model performance (area under the curve 0.54). Pneumonectomy remains associated with a high rate of perioperative mortality. Neoadjuvant chemoradiotherapy, Performance Status score and advanced disease emerged as the key variables associated with adverse outcomes after pneumonectomy in our cohort.

15 May 2019 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
MTMarcus Taylor
Marcus Taylor
HPHarshil Patel
Harshil Patel
SKSadie Khwaja
Sadie Khwaja
KRKandadai Rammohan
Kandadai Rammohan